FDA panel supports approval of Glaxo lung drug Anoro
By Toni Clarke WASHINGTON (Reuters) – A federal advisory panel recommended approval of GlaxoSmithKline Plc's new drug to treat chronic obstructive pulmonary disease(COPD), but suggested the company be required to conduct further safety studies once the drug is approved. The panel of expert advisers to the U.S. Food and Drug Administration voted 11-2 on Tuesday to approve the inhaled drug, Anoro …
FDA News – Yahoo! News Search Results
More From Around the Web
Check out these Articles
- Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixise...
- New painkiller pill set to kill people as soon as it hits shelves!
- Can an Aspirin a Day Help Prevent a Heart Attack?
- Merck's anti-blood clot drug should be approved: FDA review
- FDA’s MedWatch Safety Alerts: June 2014
- 4 Medication Safety Tips for Older Adults
- After Inexcusably Long Delay, FDA Takes First Step to Regulate E-Cigarettes...
- FDA Gives Latinas Tools to Fight Diabetes
- Sanofi Receives FDA Approval of Priftin (rifapentine) for Latent Tuberculos...
- Colorectal Cancer: What You Should Know
- U.S. FDA approves Vanda's circadian rhythm drug Hetlioz
- FDA Explores New Uses for MRI Scans
- FDA wants stricter safety rules for pelvic mesh
- FDA Approves Omidria for Use in Cataract and Other Intraocular Lens Replace...
- Here's What's Changing on Nutrition Facts Labels
- AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombi...
- Traumatic Brain Injury: FDA Research and Actions